Spots Global Cancer Trial Database for Randomized Pre-surgical Window-of-Opportunity Trial of TTI-101 in Patients With Stage II-IV Resectable HPV-negative Squamous Cell Carcinoma of the Head and Neck

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Randomized Pre-surgical Window-of-Opportunity Trial of TTI-101 in Patients With Stage II-IV Resectable HPV-negative Squamous Cell Carcinoma of the Head and Neck

Official Title: Randomized Pre-surgical Window-of-Opportunity Trial of TTI-101 in Patients With Stage II-IV Resectable HPV-negative Squamous Cell Carcinoma of the Head and Neck

Study ID: NCT05845307

Conditions

Squamous Cell Carcinoma of Head and Neck

Interventions

Control Group

TTI-101

Study Description

Brief Summary: To learn if TTI-101 can reduce the growth of HPV-negative squamous cell carcinomas of the head and neck when given before standard of care surgery.

Detailed Description: Objectives: Primary: • To determine the change in pY-STAT3 H-score in tumor tissue in post-treatment resection specimens versus pre-treatment biopsy specimens. Secondary: * To determine the safety and tolerability of pre-surgery TTI-101 in patients with Stage II-IV HPV-negative HNSCC who are planned for definitive local surgery with or without radiation. * To determine the individual pre/post treatment changes in pY-STAT3 H-scores in epithelial and stromal tumor cells. * To determine the pathologic response rate to pre-surgery TTI-101. * To determine the overall response rate (ORR) to pre-surgery TTI-101 using RECIST v1.1 criteria. * To determine the disease free, disease specific and overall survival (DFS, DSS, OS) after pre-surgery TTI-101 treatment and SOC surgery. Exploratory: * To evaluate the effects of pre-surgery TTI-101 on circulating and tumor-infiltrating immunocytes, and on the intratumoral expression of PD-1 along with other immune related molecules. * To compare outcome measures (response rate and survival) in control versus TTI-101-treated patients. * To determine the association of immunologic changes with treatment response. * To determine the association of pharmacokinetic (PK) measures with treatment response.